Napsin A Expression in Human Tumors and Normal Tissues
Novel aspartic proteinase of the pepsin family A (Napsin A, TAO1/TAO2) is a functional aspartic proteinase which is involved in the maturation of prosurfactant protein B in type II pneumocytes and the lysosomal protein catabolism in renal cells. Napsin A is highly expressed in adenocarcinomas of the...
Gespeichert in:
Veröffentlicht in: | Pathology oncology research 2021-04, Vol.27, p.613099-613099 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 613099 |
---|---|
container_issue | |
container_start_page | 613099 |
container_title | Pathology oncology research |
container_volume | 27 |
creator | Weidemann, Sören Böhle, Jan Lukas Contreras, Hendrina Luebke, Andreas M Kluth, Martina Büscheck, Franziska Hube-Magg, Claudia Höflmayer, Doris Möller, Katharina Fraune, Christoph Bernreuther, Christian Rink, Michael Simon, Ronald Menz, Anne Hinsch, Andrea Lebok, Patrick Clauditz, Till Sauter, Guido Uhlig, Ria Wilczak, Waldemar Steurer, Stefan Burandt, Eike Krech, Rainer Dum, David Krech, Till Marx, Andreas Minner, Sarah |
description | Novel aspartic proteinase of the pepsin family A (Napsin A, TAO1/TAO2) is a functional aspartic proteinase which is involved in the maturation of prosurfactant protein B in type II pneumocytes and the lysosomal protein catabolism in renal cells. Napsin A is highly expressed in adenocarcinomas of the lung and is thus commonly used to affirm this diagnosis. However, studies have shown that other tumors can also express Napsin A.
To comprehensively determine Napsin A expression in normal and tumor tissue, 11,957 samples from 115 different tumor types and subtypes as well as 500 samples of 76 different normal tissue types were evaluable by immunohistochemistry on tissue microarrays.
Napsin A expression was present in 16 different tumor types. Adenocarcinoma of the lung (85.6%), clear cell adenocarcinoma of the ovary (71.7%), clear cell adenocarcinoma of the endometrium (42.8%), papillary renal cell carcinoma (40.2%), clear cell (tubulo) papillary renal cell carcinoma (16.7%), endometrial serous carcinoma (9.3%), papillary thyroid carcinoma (9.3%) and clear cell renal cell carcinoma (8.2%) were among the tumors with the highest prevalence of Napsin A positivity. In papillary and clear cell renal cell carcinoma, reduced Napsin A expression was linked to adverse clinic-pathological features (
≤ 0.03).
This methodical approach enabled us to identify a ranking order of tumors according to their relative prevalence of Napsin A expression. The data also show that loss of Napsin A is linked to tumor dedifferentiation in renal cell carcinomas. |
doi_str_mv | 10.3389/pore.2021.613099 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8262149</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2551574479</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-bdbbc3f3db9d353b9de971c66bd00f7e5428cf85dd61eda997c59d1c4d15da423</originalsourceid><addsrcrecordid>eNpdkc1LwzAYxoMobk7vnqTgxctmvttchDGmE8a8zHNIk1Q72qYmq-h_b8rmmF7eD_K8D--bHwDXCE4IycR967ydYIjRhCMChTgBQ8QIHuMMpqdH9QBchLCBEKZc8HMwIBSzlGV4CPhKtaFskmky_2q9DaF0TRL7RVerJll3tfMhUY1JVs7XqkrWZQidDZfgrFBVsFf7PAKvj_P1bDFevjw9z6bLsaaYbse5yXNNCmJyYQgjMVqRIs15biAsUssoznSRMWM4skYJkWomDNLUIGYUxWQEHna-bZfX1mjbbL2qZOvLWvlv6VQp_7405bt8c58ywxwjKqLB3d7Au4-4-FbWZdC2qlRjXRckZgyxlNK0l97-k25c55t4nux_K-piiiq4U2nvQvC2OCyDoOyhyB6K7KHIHZQ4cnN8xGHglwL5AR8hiPo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2575515257</pqid></control><display><type>article</type><title>Napsin A Expression in Human Tumors and Normal Tissues</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Weidemann, Sören ; Böhle, Jan Lukas ; Contreras, Hendrina ; Luebke, Andreas M ; Kluth, Martina ; Büscheck, Franziska ; Hube-Magg, Claudia ; Höflmayer, Doris ; Möller, Katharina ; Fraune, Christoph ; Bernreuther, Christian ; Rink, Michael ; Simon, Ronald ; Menz, Anne ; Hinsch, Andrea ; Lebok, Patrick ; Clauditz, Till ; Sauter, Guido ; Uhlig, Ria ; Wilczak, Waldemar ; Steurer, Stefan ; Burandt, Eike ; Krech, Rainer ; Dum, David ; Krech, Till ; Marx, Andreas ; Minner, Sarah</creator><creatorcontrib>Weidemann, Sören ; Böhle, Jan Lukas ; Contreras, Hendrina ; Luebke, Andreas M ; Kluth, Martina ; Büscheck, Franziska ; Hube-Magg, Claudia ; Höflmayer, Doris ; Möller, Katharina ; Fraune, Christoph ; Bernreuther, Christian ; Rink, Michael ; Simon, Ronald ; Menz, Anne ; Hinsch, Andrea ; Lebok, Patrick ; Clauditz, Till ; Sauter, Guido ; Uhlig, Ria ; Wilczak, Waldemar ; Steurer, Stefan ; Burandt, Eike ; Krech, Rainer ; Dum, David ; Krech, Till ; Marx, Andreas ; Minner, Sarah</creatorcontrib><description>Novel aspartic proteinase of the pepsin family A (Napsin A, TAO1/TAO2) is a functional aspartic proteinase which is involved in the maturation of prosurfactant protein B in type II pneumocytes and the lysosomal protein catabolism in renal cells. Napsin A is highly expressed in adenocarcinomas of the lung and is thus commonly used to affirm this diagnosis. However, studies have shown that other tumors can also express Napsin A.
To comprehensively determine Napsin A expression in normal and tumor tissue, 11,957 samples from 115 different tumor types and subtypes as well as 500 samples of 76 different normal tissue types were evaluable by immunohistochemistry on tissue microarrays.
Napsin A expression was present in 16 different tumor types. Adenocarcinoma of the lung (85.6%), clear cell adenocarcinoma of the ovary (71.7%), clear cell adenocarcinoma of the endometrium (42.8%), papillary renal cell carcinoma (40.2%), clear cell (tubulo) papillary renal cell carcinoma (16.7%), endometrial serous carcinoma (9.3%), papillary thyroid carcinoma (9.3%) and clear cell renal cell carcinoma (8.2%) were among the tumors with the highest prevalence of Napsin A positivity. In papillary and clear cell renal cell carcinoma, reduced Napsin A expression was linked to adverse clinic-pathological features (
≤ 0.03).
This methodical approach enabled us to identify a ranking order of tumors according to their relative prevalence of Napsin A expression. The data also show that loss of Napsin A is linked to tumor dedifferentiation in renal cell carcinomas.</description><identifier>ISSN: 1532-2807</identifier><identifier>ISSN: 1219-4956</identifier><identifier>EISSN: 1532-2807</identifier><identifier>DOI: 10.3389/pore.2021.613099</identifier><identifier>PMID: 34257582</identifier><language>eng</language><publisher>Switzerland: Frontiers Media SA</publisher><subject>Antibodies ; Aspartic Acid Endopeptidases - analysis ; Aspartic Acid Endopeptidases - biosynthesis ; Biomarkers, Tumor - metabolism ; Cancer ; Esophagus ; Humans ; Kidney cancer ; Lung cancer ; Medical diagnosis ; Metastasis ; Neoplasms - metabolism ; Ovaries ; Pathology ; Proteins ; Small intestine ; Society Journal Archive ; Thyroid gland ; Tumors</subject><ispartof>Pathology oncology research, 2021-04, Vol.27, p.613099-613099</ispartof><rights>Copyright © 2021 Weidemann, Böhle, Contreras, Luebke, Kluth, Büscheck, Hube-Magg, Höflmayer, Möller, Fraune, Bernreuther, Rink, Simon, Menz, Hinsch, Lebok, Clauditz, Sauter, Uhlig, Wilczak, Steurer, Burandt, Krech, Dum, Krech, Marx and Minner.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2021 Weidemann, Böhle, Contreras, Luebke, Kluth, Büscheck, Hube-Magg, Höflmayer, Möller, Fraune, Bernreuther, Rink, Simon, Menz, Hinsch, Lebok, Clauditz, Sauter, Uhlig, Wilczak, Steurer, Burandt, Krech, Dum, Krech, Marx and Minner. 2021 Weidemann, Böhle, Contreras, Luebke, Kluth, Büscheck, Hube-Magg, Höflmayer, Möller, Fraune, Bernreuther, Rink, Simon, Menz, Hinsch, Lebok, Clauditz, Sauter, Uhlig, Wilczak, Steurer, Burandt, Krech, Dum, Krech, Marx and Minner</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-bdbbc3f3db9d353b9de971c66bd00f7e5428cf85dd61eda997c59d1c4d15da423</citedby><cites>FETCH-LOGICAL-c424t-bdbbc3f3db9d353b9de971c66bd00f7e5428cf85dd61eda997c59d1c4d15da423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262149/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262149/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34257582$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weidemann, Sören</creatorcontrib><creatorcontrib>Böhle, Jan Lukas</creatorcontrib><creatorcontrib>Contreras, Hendrina</creatorcontrib><creatorcontrib>Luebke, Andreas M</creatorcontrib><creatorcontrib>Kluth, Martina</creatorcontrib><creatorcontrib>Büscheck, Franziska</creatorcontrib><creatorcontrib>Hube-Magg, Claudia</creatorcontrib><creatorcontrib>Höflmayer, Doris</creatorcontrib><creatorcontrib>Möller, Katharina</creatorcontrib><creatorcontrib>Fraune, Christoph</creatorcontrib><creatorcontrib>Bernreuther, Christian</creatorcontrib><creatorcontrib>Rink, Michael</creatorcontrib><creatorcontrib>Simon, Ronald</creatorcontrib><creatorcontrib>Menz, Anne</creatorcontrib><creatorcontrib>Hinsch, Andrea</creatorcontrib><creatorcontrib>Lebok, Patrick</creatorcontrib><creatorcontrib>Clauditz, Till</creatorcontrib><creatorcontrib>Sauter, Guido</creatorcontrib><creatorcontrib>Uhlig, Ria</creatorcontrib><creatorcontrib>Wilczak, Waldemar</creatorcontrib><creatorcontrib>Steurer, Stefan</creatorcontrib><creatorcontrib>Burandt, Eike</creatorcontrib><creatorcontrib>Krech, Rainer</creatorcontrib><creatorcontrib>Dum, David</creatorcontrib><creatorcontrib>Krech, Till</creatorcontrib><creatorcontrib>Marx, Andreas</creatorcontrib><creatorcontrib>Minner, Sarah</creatorcontrib><title>Napsin A Expression in Human Tumors and Normal Tissues</title><title>Pathology oncology research</title><addtitle>Pathol Oncol Res</addtitle><description>Novel aspartic proteinase of the pepsin family A (Napsin A, TAO1/TAO2) is a functional aspartic proteinase which is involved in the maturation of prosurfactant protein B in type II pneumocytes and the lysosomal protein catabolism in renal cells. Napsin A is highly expressed in adenocarcinomas of the lung and is thus commonly used to affirm this diagnosis. However, studies have shown that other tumors can also express Napsin A.
To comprehensively determine Napsin A expression in normal and tumor tissue, 11,957 samples from 115 different tumor types and subtypes as well as 500 samples of 76 different normal tissue types were evaluable by immunohistochemistry on tissue microarrays.
Napsin A expression was present in 16 different tumor types. Adenocarcinoma of the lung (85.6%), clear cell adenocarcinoma of the ovary (71.7%), clear cell adenocarcinoma of the endometrium (42.8%), papillary renal cell carcinoma (40.2%), clear cell (tubulo) papillary renal cell carcinoma (16.7%), endometrial serous carcinoma (9.3%), papillary thyroid carcinoma (9.3%) and clear cell renal cell carcinoma (8.2%) were among the tumors with the highest prevalence of Napsin A positivity. In papillary and clear cell renal cell carcinoma, reduced Napsin A expression was linked to adverse clinic-pathological features (
≤ 0.03).
This methodical approach enabled us to identify a ranking order of tumors according to their relative prevalence of Napsin A expression. The data also show that loss of Napsin A is linked to tumor dedifferentiation in renal cell carcinomas.</description><subject>Antibodies</subject><subject>Aspartic Acid Endopeptidases - analysis</subject><subject>Aspartic Acid Endopeptidases - biosynthesis</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cancer</subject><subject>Esophagus</subject><subject>Humans</subject><subject>Kidney cancer</subject><subject>Lung cancer</subject><subject>Medical diagnosis</subject><subject>Metastasis</subject><subject>Neoplasms - metabolism</subject><subject>Ovaries</subject><subject>Pathology</subject><subject>Proteins</subject><subject>Small intestine</subject><subject>Society Journal Archive</subject><subject>Thyroid gland</subject><subject>Tumors</subject><issn>1532-2807</issn><issn>1219-4956</issn><issn>1532-2807</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkc1LwzAYxoMobk7vnqTgxctmvttchDGmE8a8zHNIk1Q72qYmq-h_b8rmmF7eD_K8D--bHwDXCE4IycR967ydYIjRhCMChTgBQ8QIHuMMpqdH9QBchLCBEKZc8HMwIBSzlGV4CPhKtaFskmky_2q9DaF0TRL7RVerJll3tfMhUY1JVs7XqkrWZQidDZfgrFBVsFf7PAKvj_P1bDFevjw9z6bLsaaYbse5yXNNCmJyYQgjMVqRIs15biAsUssoznSRMWM4skYJkWomDNLUIGYUxWQEHna-bZfX1mjbbL2qZOvLWvlv6VQp_7405bt8c58ywxwjKqLB3d7Au4-4-FbWZdC2qlRjXRckZgyxlNK0l97-k25c55t4nux_K-piiiq4U2nvQvC2OCyDoOyhyB6K7KHIHZQ4cnN8xGHglwL5AR8hiPo</recordid><startdate>20210420</startdate><enddate>20210420</enddate><creator>Weidemann, Sören</creator><creator>Böhle, Jan Lukas</creator><creator>Contreras, Hendrina</creator><creator>Luebke, Andreas M</creator><creator>Kluth, Martina</creator><creator>Büscheck, Franziska</creator><creator>Hube-Magg, Claudia</creator><creator>Höflmayer, Doris</creator><creator>Möller, Katharina</creator><creator>Fraune, Christoph</creator><creator>Bernreuther, Christian</creator><creator>Rink, Michael</creator><creator>Simon, Ronald</creator><creator>Menz, Anne</creator><creator>Hinsch, Andrea</creator><creator>Lebok, Patrick</creator><creator>Clauditz, Till</creator><creator>Sauter, Guido</creator><creator>Uhlig, Ria</creator><creator>Wilczak, Waldemar</creator><creator>Steurer, Stefan</creator><creator>Burandt, Eike</creator><creator>Krech, Rainer</creator><creator>Dum, David</creator><creator>Krech, Till</creator><creator>Marx, Andreas</creator><creator>Minner, Sarah</creator><general>Frontiers Media SA</general><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210420</creationdate><title>Napsin A Expression in Human Tumors and Normal Tissues</title><author>Weidemann, Sören ; Böhle, Jan Lukas ; Contreras, Hendrina ; Luebke, Andreas M ; Kluth, Martina ; Büscheck, Franziska ; Hube-Magg, Claudia ; Höflmayer, Doris ; Möller, Katharina ; Fraune, Christoph ; Bernreuther, Christian ; Rink, Michael ; Simon, Ronald ; Menz, Anne ; Hinsch, Andrea ; Lebok, Patrick ; Clauditz, Till ; Sauter, Guido ; Uhlig, Ria ; Wilczak, Waldemar ; Steurer, Stefan ; Burandt, Eike ; Krech, Rainer ; Dum, David ; Krech, Till ; Marx, Andreas ; Minner, Sarah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-bdbbc3f3db9d353b9de971c66bd00f7e5428cf85dd61eda997c59d1c4d15da423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Aspartic Acid Endopeptidases - analysis</topic><topic>Aspartic Acid Endopeptidases - biosynthesis</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cancer</topic><topic>Esophagus</topic><topic>Humans</topic><topic>Kidney cancer</topic><topic>Lung cancer</topic><topic>Medical diagnosis</topic><topic>Metastasis</topic><topic>Neoplasms - metabolism</topic><topic>Ovaries</topic><topic>Pathology</topic><topic>Proteins</topic><topic>Small intestine</topic><topic>Society Journal Archive</topic><topic>Thyroid gland</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weidemann, Sören</creatorcontrib><creatorcontrib>Böhle, Jan Lukas</creatorcontrib><creatorcontrib>Contreras, Hendrina</creatorcontrib><creatorcontrib>Luebke, Andreas M</creatorcontrib><creatorcontrib>Kluth, Martina</creatorcontrib><creatorcontrib>Büscheck, Franziska</creatorcontrib><creatorcontrib>Hube-Magg, Claudia</creatorcontrib><creatorcontrib>Höflmayer, Doris</creatorcontrib><creatorcontrib>Möller, Katharina</creatorcontrib><creatorcontrib>Fraune, Christoph</creatorcontrib><creatorcontrib>Bernreuther, Christian</creatorcontrib><creatorcontrib>Rink, Michael</creatorcontrib><creatorcontrib>Simon, Ronald</creatorcontrib><creatorcontrib>Menz, Anne</creatorcontrib><creatorcontrib>Hinsch, Andrea</creatorcontrib><creatorcontrib>Lebok, Patrick</creatorcontrib><creatorcontrib>Clauditz, Till</creatorcontrib><creatorcontrib>Sauter, Guido</creatorcontrib><creatorcontrib>Uhlig, Ria</creatorcontrib><creatorcontrib>Wilczak, Waldemar</creatorcontrib><creatorcontrib>Steurer, Stefan</creatorcontrib><creatorcontrib>Burandt, Eike</creatorcontrib><creatorcontrib>Krech, Rainer</creatorcontrib><creatorcontrib>Dum, David</creatorcontrib><creatorcontrib>Krech, Till</creatorcontrib><creatorcontrib>Marx, Andreas</creatorcontrib><creatorcontrib>Minner, Sarah</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pathology oncology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weidemann, Sören</au><au>Böhle, Jan Lukas</au><au>Contreras, Hendrina</au><au>Luebke, Andreas M</au><au>Kluth, Martina</au><au>Büscheck, Franziska</au><au>Hube-Magg, Claudia</au><au>Höflmayer, Doris</au><au>Möller, Katharina</au><au>Fraune, Christoph</au><au>Bernreuther, Christian</au><au>Rink, Michael</au><au>Simon, Ronald</au><au>Menz, Anne</au><au>Hinsch, Andrea</au><au>Lebok, Patrick</au><au>Clauditz, Till</au><au>Sauter, Guido</au><au>Uhlig, Ria</au><au>Wilczak, Waldemar</au><au>Steurer, Stefan</au><au>Burandt, Eike</au><au>Krech, Rainer</au><au>Dum, David</au><au>Krech, Till</au><au>Marx, Andreas</au><au>Minner, Sarah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Napsin A Expression in Human Tumors and Normal Tissues</atitle><jtitle>Pathology oncology research</jtitle><addtitle>Pathol Oncol Res</addtitle><date>2021-04-20</date><risdate>2021</risdate><volume>27</volume><spage>613099</spage><epage>613099</epage><pages>613099-613099</pages><issn>1532-2807</issn><issn>1219-4956</issn><eissn>1532-2807</eissn><abstract>Novel aspartic proteinase of the pepsin family A (Napsin A, TAO1/TAO2) is a functional aspartic proteinase which is involved in the maturation of prosurfactant protein B in type II pneumocytes and the lysosomal protein catabolism in renal cells. Napsin A is highly expressed in adenocarcinomas of the lung and is thus commonly used to affirm this diagnosis. However, studies have shown that other tumors can also express Napsin A.
To comprehensively determine Napsin A expression in normal and tumor tissue, 11,957 samples from 115 different tumor types and subtypes as well as 500 samples of 76 different normal tissue types were evaluable by immunohistochemistry on tissue microarrays.
Napsin A expression was present in 16 different tumor types. Adenocarcinoma of the lung (85.6%), clear cell adenocarcinoma of the ovary (71.7%), clear cell adenocarcinoma of the endometrium (42.8%), papillary renal cell carcinoma (40.2%), clear cell (tubulo) papillary renal cell carcinoma (16.7%), endometrial serous carcinoma (9.3%), papillary thyroid carcinoma (9.3%) and clear cell renal cell carcinoma (8.2%) were among the tumors with the highest prevalence of Napsin A positivity. In papillary and clear cell renal cell carcinoma, reduced Napsin A expression was linked to adverse clinic-pathological features (
≤ 0.03).
This methodical approach enabled us to identify a ranking order of tumors according to their relative prevalence of Napsin A expression. The data also show that loss of Napsin A is linked to tumor dedifferentiation in renal cell carcinomas.</abstract><cop>Switzerland</cop><pub>Frontiers Media SA</pub><pmid>34257582</pmid><doi>10.3389/pore.2021.613099</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1532-2807 |
ispartof | Pathology oncology research, 2021-04, Vol.27, p.613099-613099 |
issn | 1532-2807 1219-4956 1532-2807 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8262149 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
subjects | Antibodies Aspartic Acid Endopeptidases - analysis Aspartic Acid Endopeptidases - biosynthesis Biomarkers, Tumor - metabolism Cancer Esophagus Humans Kidney cancer Lung cancer Medical diagnosis Metastasis Neoplasms - metabolism Ovaries Pathology Proteins Small intestine Society Journal Archive Thyroid gland Tumors |
title | Napsin A Expression in Human Tumors and Normal Tissues |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A14%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Napsin%20A%20Expression%20in%20Human%20Tumors%20and%20Normal%20Tissues&rft.jtitle=Pathology%20oncology%20research&rft.au=Weidemann,%20S%C3%B6ren&rft.date=2021-04-20&rft.volume=27&rft.spage=613099&rft.epage=613099&rft.pages=613099-613099&rft.issn=1532-2807&rft.eissn=1532-2807&rft_id=info:doi/10.3389/pore.2021.613099&rft_dat=%3Cproquest_pubme%3E2551574479%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2575515257&rft_id=info:pmid/34257582&rfr_iscdi=true |